• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Century Therapeutics, Inc. - Common Stock (NQ:IPSC)

1.530 -0.080 (-4.97%)
Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 802,960
Open 1.640
Bid (Size) 1.550 (200)
Ask (Size) 1.700 (1,200)
Prev. Close 1.610
Today's Range 1.465 - 1.670
52wk Range 0.4350 - 3.040
Shares Outstanding 85,029,042
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Century Therapeutics' CNTY-813 Demonstrates Continued Advancement Toward the Clinic Via Nonclinical Data Presented at EASD 2026
October 02, 2026
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics Appoints Joseph Truitt to Board of Directors
September 09, 2026
From Century Therapeutics, Inc.
Via GlobeNewswire

Performance

52-Week Range 49.7% below 52-week high
1.530
0.4352W Low 3.0452W High
1 Week 11.0% below 1-week high
1.471W Low 1.721W High

Century Therapeutics, Inc. - Common Stock (IPSC) traded between $0.43 and $3.04 over the past 52 weeks and last traded at $1.53, 49.7% below its 52-week high. Over the past week it ranged between $1.47 and $1.72.

Past 12 Months
-8.4%
-27.5%
-36.2%
-30.1%
+53.8%
+207.5%
1W -$0.14
1M -$0.58
3M -$0.87
6M -$0.66
YTD +$0.54
1Y +$1.03

IPSC was +207.5% over the past year, -30.1% over six months, +53.8% year to date, -8.4% in the last week.

12 Months vs Market
IPSC
+207.5%
DIA
+9.9%
SPY
+15.0%
QQQ
+23.7%
IWM
+15.4%

Over the past 12 months IPSC returned +207.5% versus DIA (Dow) +9.9%, SPY (S&P 500) +15.0%, QQQ (Nasdaq 100) +23.7% and IWM (Russell 2000) +15.4%.

Volume & Liquidity 1.25× 3-mo avg
Today 802,960 3-mo avg 643.8K
1W
562.3K
1M
512.6K
3M
643.8K
6M
964.3K
YTD
1.3M
1Y
1.3M

IPSC most recently traded 802,960 shares against a 3-month average daily volume of 643.8K.

More News

Read More
News headline image
Century Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates
August 12, 2026
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics Selected for Oral Presentations of CNTY-813 Preclinical Data at EASD 2026 and Breakthrough T1D® Clinical & Research Congress 2026
July 09, 2026
From Century Therapeutics, Inc.
Via GlobeNewswire
Century Therapeutics (NASDAQ:IPSC) Reports Narrower Loss, Extended Cash Runway to 2029 ↗
March 12, 2026
Via Chartmill
News headline image
New CNTY-813 Preclinical Data Demonstrate Durable Glucose Control, Immune Evasion Under Alloimmune Pressure, and Scalable Manufacturing at ADA 2026
June 08, 2026
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
A New $21 Million Position Signals Confidence in This Post-IPO Drug Developer ↗
May 31, 2026
Via The Motley Fool
Topics Initial Public Offering
News headline image
Century Therapeutics Reports First Quarter Financial Results and Business Updates
May 13, 2026
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics Selected for Oral Presentation of CNTY‑813 Preclinical Data at the American Diabetes Association 86th Scientific Sessions
April 30, 2026
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics Reports Full Year 2025 Financial Results and Business Updates
March 12, 2026
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics to Participate in Upcoming Investor Conferences in March
February 25, 2026
From Century Therapeutics, Inc.
Via GlobeNewswire
Here are the top movers in Thursday's session. ↗
January 08, 2026
Via Chartmill
These stocks are gapping in today's session ↗
January 08, 2026
Via Chartmill
News headline image
Century Therapeutics Secures Oversubscribed $135 Million Private Placement Financing to Support Lead Program, CNTY-813, a Potentially Curative Therapy for Type 1 Diabetes
January 08, 2026
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics Appoints Accomplished Biotechnology Leaders Dr. Han Lee and Dr. Martin Murphy to Board of Directors
December 09, 2025
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics to Participate in Piper Sandler 37th Annual Healthcare Conference
November 25, 2025
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
November 13, 2025
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics Announces New Beta Islet Program for Type 1 Diabetes
November 13, 2025
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics to Present at Chardan’s 9th Annual Genetic Medicines Conference
October 14, 2025
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference
August 22, 2025
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Reports Flat Loss in Fiscal Q2 ↗
August 14, 2025
Via The Motley Fool
News headline image
Century Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
August 14, 2025
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monday's after hours session: top gainers and losers ↗
July 07, 2025
Via Chartmill
News headline image
Century Therapeutics Announces Two Upcoming Presentations at the EULAR 2025 Congress
May 28, 2025
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
May 15, 2025
From Century Therapeutics, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Century Therapeutics, Inc. - Common Stock publicly traded?
Yes, Century Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Century Therapeutics, Inc. - Common Stock trade on?
Century Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Century Therapeutics, Inc. - Common Stock?
The ticker symbol for Century Therapeutics, Inc. - Common Stock is IPSC on the Nasdaq Stock Market
What is the current price of Century Therapeutics, Inc. - Common Stock?
The current price of Century Therapeutics, Inc. - Common Stock is 1.530
When was Century Therapeutics, Inc. - Common Stock last traded?
The last trade of Century Therapeutics, Inc. - Common Stock was at 10/02/26 04:00 PM ET
What is the market capitalization of Century Therapeutics, Inc. - Common Stock?
The market capitalization of Century Therapeutics, Inc. - Common Stock is 130.09M
How many shares of Century Therapeutics, Inc. - Common Stock are outstanding?
Century Therapeutics, Inc. - Common Stock has 130M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap